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Abstract: The subgenus Bryophyllum includes about 25 plant species native to Madagascar, and is
widely used in traditional medicine worldwide. Different formulations from Bryophyllum have
been employed for the treatment of several ailments, including infections, gynecological disorders,
and chronic diseases, such as diabetes, neurological and neoplastic diseases. Two major families of
secondary metabolites have been reported as responsible for these bioactivities: phenolic compounds
and bufadienolides. These compounds are found in limited amounts in plants because they are
biosynthesized in response to different biotic and abiotic stresses. Therefore, novel approaches should
be undertaken with the aim of achieving the phytochemical valorization of Bryophyllum sp., allowing a
sustainable production that prevents from a massive exploitation of wild plant resources. This review
focuses on the study of phytoconstituents reported on Bryophyllum sp.; the application of plant
tissue culture methodology as a reliable tool for the valorization of bioactive compounds; and the
application of machine learning technology to model and optimize the full phytochemical potential
of Bryophyllum sp. As a result, Bryophyllum species can be considered as a promising source of plant
bioactive compounds, with enormous antioxidant and anticancer potential, which could be used for
their large-scale biotechnological exploitation in cosmetic, food, and pharmaceutical industries.
Keywords: Bryophyllum; traditional medicine; secondary metabolism; bioactive and phenolic
compounds; bufadienolides; antioxidants; cytotoxic activity; plant tissue culture; artificial intelligence
1. Introduction
The genus Kalanchoe (Adanson, 1736 [1]) belongs to the Crassulaceae family and comprises
150 to 200 succulent species native to Madagascar and naturalized across Africa, South America,
and Asia [2,3]. Kalanchoe constitutes a complex genus with an intricate taxonomy, not yet clearly
elucidated. Two different trends have been remarkable throughout the published literature concerning
both its nomenclature and systematics [4]. Authors disagree whether the classification is based on a single
genus called Kalanchoe (sensu lato) or three separate sections: Kalanchoe (sensu stricto), Bryophyllum Kahl.
(Salisbury, 1805 [5]), and Kitchingia (Baker, 1881 [6]). However, other authors propose a three-subgenera
classification of the genus Kalanchoe, due to different evolutive arguments, morphological traits [7] and
molecular analyses [8], including Kalanchoe, Bryophyllum and Calophygia [4]. Amongst the different
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subgenera, the subgenus Bryophyllum includes around 25 species, endemic to Madagascar [9] that
gained much interest on plant science research, as they are considered model plants for different
physiological features: the Crassulacean Acid Metabolism (CAM) [10], vegetative reproduction [11],
plant cell regeneration [12], and a source of therapeutical compounds [13]. Nevertheless, the most
relevant feature associated to this subgenus is the use of their constitutive species in the traditional
medicine worldwide, thus considering Bryophyllum sp. as medicinal plants, due to their associated
bioactivities [13].
CAM photosynthesis is an advantageous adaptative strategy that enables plant adaptation to
arid ecosystems, as it is the case of the whole Kalanchoe genus [14]. Bryophyllum species present a
flexible CAM regime, with no time restriction on CO2 uptake, which is fixed at night [15]. On the other
hand, Bryophyllum sp. present a highly specialized asexual reproductive mechanism, based on the
symmetric plantlet development along the leaf margins or leaf tips of adult plants (Figure 1) [12,16].
Such clonal-spreading reproductive mechanism is driven by a complex phenomenon that combines
both embryogenic and organogenetic events that has not been fully elucidated to date [17–21]. Both the
metabolic and reproductive patterns found on Bryophyllum sp. contribute to the invasiveness of these
species. It allows them a rapid colonization of unexplored territories with high adaptative efficiency,
which has contributed to their worldwide naturalization [22,23].
Figure 1. In vitro-cultured plants of B. daigremontianum (left); B. × houghtonii (center); and B. tubiflorum
(right). Bars = 1 cm; arrows indicate plantlets formed asexually on leaf margins. Original figure.
Bryophyllum and other Kalanchoe species have been widely used in the traditional medicine
of vast regions throughout Africa, South America, and Asia [24]. Because of its wide distribution
and ubiquitous medicinal use, much research on this subgenus has focused on Bryophyllum pinnatum
(Lam.) Oken [25–27]; however, there is an extensive variety of other species that have also been
exploited in Ethnomedicine, such as: B. daigremontianum (Raym.-Hamet et Perr.) Berg. [28], B. tubiflorum
Harv. [29,30], and B. × houghtonii D.B. Ward (syn. B. daigremontianum × tubiflorum) [31]. Leaf and
root-derived formulations have been mostly used for the treatment of several common illnesses such
as burns, wounds, insect bites, skin diseases, cough, fever or several infections, and chronic diseases,
such as diabetes, and neurological and neoplastic diseases (Table 1).
Pharmaceuticals 2020, 13, 444 3 of 23
Table 1. Ethnobotanical uses of Bryophyllum species.
Species Ethnobotanical Uses Plant Organ Locations 1 References
B. crenatum (Andr.) Baker
Wounds, smallpox, otitis, cough, asthma, palpitations,
headache, abscesses, convulsions, general debility, diabetes,






Leucorrhea, dysmenorrheal, carminative, psychic agitation,
anxiety, restlessness Leaves Bangladesh [28,36]
B. fedtschenkoi Raym.-Hamet et Perr. Analgesic, cytotoxic, antimicrobial treatment LeavesAerial parts Woody stems Brazil [37–39]
B. mortagei (Raym.-Hamet et Perr.)
G.E. Wickens





Mexico, Colombia, Indonesia [37,40–42]
B. pinnatum (Lam.) Oken
Wounds, burns, coughs, earache, headache, muscle pain,
asthma, bronchitis, pneumonia, arthritis, rheumatism,
ulcers, diabetes, urinary bladder stones, dysentery, diarrhea,
vermifuge, antibacterial, insect bites, fevers, menstrual
disorders, nausea, tumors, gynecology
Leaves
Roots
Nigeria, Uganda, Madagascar, India,
China, Vietnam, Bangladesh, Australia,
Brazil, Peru, Trinidad and Tobago
[43–52]
B. serratum (Mann. and Boit.) Blanco Pain, inflammation, fever, antiviral Stems Taiwan [53,54]
B. tubiflorum Harv. Wounds, epilepsy, vermifuge, neoplastic diseases Leaves Brazil, Ethiopia [29,30]
1 Locations where the ethnobotanical uses have been reported.
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The great therapeutic potential reported on Bryophyllum sp. [39] has promoted in-depth
phytochemical analysis to adequately evaluate its biological and pharmacological properties [55,56].
Several authors have demonstrated the whole bioactive potential of Bryophyllum-derived extracts,
acting as multifaceted agents.
The anti-inflammatory activity of Bryophyllum extracts has been determined by different methods
using both in vivo and in vitro models. For instance, aqueous extracts from B. pinnatum were
shown to exert a relevant effect against croton oil-induced ear edema and carrageenan-induced
paw edema in murine models, driven by a decrease in pro-inflammatory cytokines [57]. Moreover,
different flavonoids produced by B. tubiflorum showed an inhibitory effect on nitric oxide production
by lipopolysaccharide-induced macrophage in vitro RAW264.7 cell line [58].
The antimicrobial activity attributed to Bryophyllum extracts was shown to present a high
effectiveness against a wide range of both bacterial and fungal activities. In this sense, hydroethanolic
extracts from B. fedtschenkoi showed a strong inhibitory effect against different antimicrobial resistant
strains from the ESKAPE complex, including both Gram-negative and Gram-positive bacteria [37].
Similarly, the bactericidal effect of B. crenatum leaf juice against Bacillus subtilis and Klebsiella pneumoniae
was also reported, as well as high effectiveness of methanol extracts from B. pinnatum to Gram-positive
bacteria [34]. Moreover, different isolated fractions from B. daigremontianum ethanolic extracts promoted
a potent activity against Safase S-04 yeast strain, fungi, such as Candida albicans and Aspergillus niger,
and bacteria, including Staphylococcus aureus and Escherichia coli [59]. Furthermore, the antiviral activity
of Bryophyllum extracts has been also assessed for relevant viral diseases. It is the case of the antiviral
activity of kaempferol derivatives from B. daigremontianum against Herpes Simplex Virus (HSV) types
1 and 2 [60] and bryophyllin B from B. pinnatum as a potent inhibitor of Human Immunodeficiency
Virus (HIV) [61].
Additionally, the analgesic and sedative properties of Bryophyllum extracts were evaluated using
in vivo murine models, indicating that leaf extracts from B. crenatum showed a protective effect against
formalin and acetic acid-induced pain and inhibited the manifestation of seizures under convulsant
agents application [32].
The antioxidant properties of Bryophyllum extracts have been widely reported by a plethora
of different methods. The radical scavenging activity against 2,2-diphenyl-picryl-hydrazyl (DPPH),
superoxide anion and nitric oxide of B. daigremontianum, B. tubiflorum, B. × houghtonii, and B. pinnatum leaf
and aerial part extracts was reported [62,63]. The inhibition of lipid peroxidation by hydromethanolic
extracts from aerial parts of B. daigremontianum, B. tubiflorum, and B. × houghtonii, cultured in vitro was
also determined [64]. Moreover, cell-based in vitro antioxidant assays have been performed for the
inhibition of lipid peroxidation of root extracts from B. daigremontianum [24].
Bryophyllum extracts have been also shown to present insecticidal properties, as a consequence
of bufadienolide production, as reviewed later. In this sense, methanolic leaf extracts from
B. daigremontianum, B. pinnatum, and B. × houghtonii showed an intense effect against silkworm
larvae (Bombyx mori) [65–67].
Moreover, cardioprotective and antihypertensive properties were attributed to different
Bryophyllum sp. [68]. For instance, the aqueous extracts of B. pinnatum have been shown to exhibit
in vivo antihypertensive activity on high salt-loaded rats models [69]. Furthermore, isolates from
B. daigremontianum root extracts developed an in vitro anti-thrombotic activity [70].
Against all the bioactivities associated with Bryophyllum sp., the cytotoxic activity gained much
interest during the phytochemical characterization of these species [71]. A great variety of in vitro
models have been employed for the determination of cytotoxic and anti-cancer activities on different
Bryophyllum species, whose extracts have been tested against a high number of cancer cell lines [13,68].
Due to the relevance of this bioactivity, the cytotoxic properties of Bryophyllum extracts are included
during this review.
Finally, there are additional health-enhancing properties related to Bryophyllum sp., as it is the case
of hepatoprotective, antidiabetic activities. Thus, the leaf juice and aqueous of B. pinnatum showed
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a marked in vivo hepatoprotective effect on carbon tetrachloride-induced hepatotoxicity in rats [72],
as well as hypoglycemic and hypocholesterolemic effects in streptozotocin-induced diabetic rats [73].
As a result, the combination of all bioactivities attributed to Bryophyllum sp. aroused the interest
in the study of their great therapeutic potential, which is a challenge, as it is an unexplored subgenus
with countless potential as a health promoter. This is a systematic review in which general search
engines, including PubMed, the Web of Science, and Google Scholar were employed, according to
Preferred Reported Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
2. Bryophyllum sp. Secondary Metabolites as Antioxidants and Anticancer Agents
It is now well-known that the full set of bioactivities attributed to Bryophyllum sp. is developed
by a plethora of phytoconstituents, including phenolic compounds, bufadienolides, organic salts,
terpenoids and fatty acids [55]. Phytoconstituents are considered secondary metabolites, since they
are biosynthesized by induction of secondary metabolism, which is responsible for the defensive and
adaptative plant response against environmental threads and biotic stress [74,75]. Phenolic compounds
and bufadienolides are considered the two main families of secondary metabolites of Bryophyllum sp.,
widely distributed throughout the subgenus [13]. Furthermore, they are responsible for the bioactivity
associated with Bryophyllum sp. and, consequently, a deeper insight into these compounds will
be provided.
2.1. Phenolic Compounds
Two major subfamilies of phenolic compounds have been widely reported for Bryophyllum sp.:
phenolic acids and flavonoids [76,77], which have been recently found to accumulate inside highly
specialized leaf cells, called idioblasts [78].
The antioxidant activity of Bryophyllum phenolic compounds, focused on the free-radical
scavenging activity, has been largely determined [63,79]. Recently, the antioxidant capacity of
Bryophyllum extracts for preventing the lipid oxidation of omega-3 enriched fish oil emulsions
was reported, thus conferring a valuable approach for the application of Bryophyllum-derived
by-products in the food and pharmacological industries [64]. In the same way, the polyphenols from
Bryophyllum-derived extracts may be efficiently purified using environmental-friendly procedures,
like the use of activated carbon [80]. These approaches have been developed in order to allow the
industrial exploitation of Bryophyllum polyphenols, due to the increasing interest in the research of
these medicinal plants.
The great diversity of bioactivities described for these compounds places the phenolic compounds
of Bryophyllum sp. as one of the main families of plant secondary metabolites that boost the
phytochemical potential of this subgenus [62,64,81].
2.1.1. Phenolic Acids
Three species of Bryophyllum present high content in phenolic acids: B. pinnatum, B. daigremontianum,
and B. tubiflorum, mostly located in leaf tissues (Table 2) [76,82]. Both subfamilies of phenolic acids
have identified compounds in either free or glycosylated forms. Caffeic acid and ferulic acid are the
most abundant cinnamic acids, while within the benzoic acids it is protocatechuic acid. β-resorcylic
and γ-rosorcylic acids have also been referenced, although these are more unusual. [63].
Concerning bioactivities, phenolic acids are considered powerful antioxidants whose activity
depends on the number, position, and combination of hydroxyl groups within their structure [83].
Potential therapeutic properties for them have also been reported, as they promote antimicrobial,
antiviral, cytotoxic, and anti-inflammatory activities [84–87]. Phenolic acids from Bryophyllum-derived
extracts have already been related to the development of antibacterial and antifungal activity against
a series of pathogenic microorganisms [88], antioxidant activity, and cytotoxicity against human
lymphoblastic leukemia J45 and H9 T-cell lines [63].
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Table 2. Phenolic acids reported in Bryophyllum sp.
Subfamily Compound 1 Species 2 References
Cinnamic acids
p-Coumaric acid BD, BP, BT [63,82,88–90]
Caffeic acid BD, BP, BT [63,79,88,91]
Chlorogenic acid BD, BT [63,92]
Ferulic acid BD, BP, BT [26,63,82,92,93]
Benzoic acids
p-Hydroxybenzoic acid BD, BP, BT [91]
Protocatechuic acid BD, BP, BT [26,63,82,91,93]
Vanillic acid BT [58,78]
Gallic acid BD, BP, BT [63,78,82,88,90,91,93]
Syringic acid BD, BP, BT [63,78,90]
1 Compounds are named as their free-form to simplify the identification. 2 BD: B. daigremontianum; BP: B. pinnatum;
BT: B. tubiflorum.
2.1.2. Flavonoids
Flavonoids are universally found in Bryophyllum sp. in O-glycosylated form. To a large extent,
they have been reported in three species, namely: B. pinnatum, B. daigremontianum and B. tubiflorum
(Table 3). The flavonol glycosides were shown as the most abundant subfamily of flavonoids, showing a
restricted accumulation on leaf tissues [13,76,90]. Both kaempferol and quercetin glycosides were
found in Bryophyllum species [39,94,95]. Other flavonoid subfamilies, such as flavones and catechins,
have also been reported, and a number of anthocyanins have been isolated from the flowers of different
species [39,96], which are stored in the foliar idioblasts of B. daigremontianum [82] and B. tubiflorum [78].
The antioxidant activity of flavonoids is directly proportional to the number and position of
hydroxyl groups in their structure [97], that assist in the dissipation of electrons generated after
UV-overexposure [98]. Additionally, they also prevent lipid peroxidation [99] (by decomposing
lipid peroxides and scavenging harmful free-radicals) and develop an effective metal chelation
activity [100]. The free-radical scavenging [62,101,102] and lipid oxidation preventing activities [64] of
Bryophyllum-derived extracts rich in flavonoids have already been reported. Other bioactivities, such
as antibacterial [103], antiviral [104], cytotoxic [105], anti-inflammatory [106], cardioprotective [107],
sedative and anti-diabetic activities [108] have been associated to flavonoids. These bioactivities
have been extensively studied for Bryophyllum sp. and have also been related to flavonoid content,
mainly using B. pinnatum as a plant model [88,89,94,95,109,110].
Table 3. Flavonoids reported in Bryophyllum sp.
Subfamily Compound 1 Species 2 References
Flavanones Naringenin BT [92]
Flavones
Luteolin BP [89,94,111]








Quercetin BD, BP, BT [58,77,78,88,89,92,94,95,109]
Kaempferol BD, BP, BT [77,78,88–90,92,102,109,112]
Quercitrin BP [109,112]
Myricetin BD, BP, BT [77,90,92]
Rutin BP [89,94]
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Table 3. Cont.





1 Flavonoids are named as their free-form to simplify the identification. 2 BD: B. daigremontianum; BP: B. pinnatum;
BT: B. tubiflorum.
2.2. Bufadienolides
Bufadienolides constitute a subfamily within cardiac glycosides family of secondary metabolites
and they are considered polyhydroxy C-24 steroids, presenting an α-pyrone ring at the C-17β position
(Figure 2) [113]. Bufadienolides presence in Bryophyllum species is genotype and organ dependent [68],
being four species the most representative sources of these compounds: B. daigremontianum,
B. × houghtonii, B. tubiflorum, and B. pinnatum (Table 4). Universally-distributed bufadienolides, such as
bersaldegenin and bryophyllin derivatives [77,114], can be found together with genotype-specific
compounds, such as kalanchosides [115] and kalanhybrins [71].
Figure 2. Basic molecular structure of bufadienolides.
As cardiac glycosides, the original bioactivity attributed to bufadienolides is their cardiotonic
activity, acting as inhibitors of the sodium pump at the myocardial tissue [116]. However, its reduced
therapeutic window conditions its efficacy, allowing eventual cardiotoxic events due to overdosage [117].
In fact, the accidental consumption of Bryophyllum species by different mammals is one of the leading
causes of cattle mortality in Africa [118], with reporting episodes of stroke, subendocardial hemorrhages,
and heart tissue necrosis [119]. The biosynthesis of bufadienolides is a plant defensive mechanism
against insect and herbivore attacks. They have already been reported as effective insecticidal
compounds [31].
Bufadienolides have also been described as potent anticancer agents, as demonstrated by a number
of in vitro studies with multiple cancer cell lines (Table 4) [120]. Nevertheless, their inherent toxicity
difficult their administration in animal and human models [121]. Current research on these compounds
is focused on finding effective and safer semi-synthetic derivatives [122].
Table 4 shows the associated bioactivities of identified bufadienolides in Bryophyllum sp., with a
special focus on the cytotoxic activity of these compounds, being effective against relevant cancer cell
lines, mainly those derived from breast, ovarian and lung carcinomas [71,115].
The bioactivity of phenolic and bufadienolides compounds reveals an unexploited phytochemical
potential associated with Bryophyllum sp. However, research on these secondary metabolites is still
very limited, since their concentration and activity depend on adaptive responses of plants, which is
why low-yield extraction protocols have been reported [61,123]. Consequently, in order to explore the
phytochemical properties of these medicinal plants, the establishment of efficient biotechnological
approaches is required to achieve the valorization of Bryophyllum subgenus.
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Table 4. Bufadienolides identified in Bryophyllum sp. and their associated bioactivities.







Moderate antioxidant activity using in vitro blood plasma
model under peroxynitrite-induced oxidative stress.
Effective for prevention of lipid hydroperoxides generation
and thiobarbituric acid-reactive substances (TBARS)
[24]
BP Leaves Bryophyllin A and C Insecticidal against silkworm larvae [66]
BH Leaves
Bryophyllin A and C, bersaldegenin-1-acetate,
bersaldegenin-3-acetate, bersaldegenin-1,3,5-orthoacetate,
daigremontianin, methyl daigremoniate
Insecticidal against silkworm larvae, except for
bersaldegenin-1-acetate.
Cytotoxic effect of bersaldegenin-1,3,5-orthoacetate and
daigremontianin against induced Raji cell line
(Burkitt’s lymphoma); inhibition of Epstein–Barr virus
[31,67]
BH Whole plant Kalanhybrins A, B and C, bersaldegenin-1-acetate,bersaldegenin-3-acetate
Cytotoxic activity of bersaldegenin derivatives against
human breast MCF-7 cancer cell line, human lung
carcinoma NCI-H460 and glioblastoma SF-268 cell line
[71]
BD Roots Kalandaigremosides A-H nd [124]
BP Whole plant Bryophyllin A and B, bersaldegenin-3-acetate
Cytotoxic effect against keratin-forming tumor KB cell line,
adenocarcinomic human alveolar basal epithelial A-549 cell










BD Leaves Bersaldegenin-1,3,5-orthoacetate, daigremontianin Insecticidal against silkworm larvae [65]
BP Leaves Bersaldegenin-1-acetate, bersaldegenin-3-acetate,bersaldegenin-1,3,5-orthoacetate, bryophyllin A nd [90]
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Cytotoxic activity against human ovarian cancer SKOV-3
cell line, cervical adenocarcinoma HeLa S3 cell line and
malignant melanoma A375 cell line.
Antimicrobial activity against Corynebacterium diphtheriae,
Staphylococcus aureus, Staphylococcus epidermidis,
and Enterococcus hirae
[77,126]
BT Whole plant Kalantubosides A and B, bryophyllin A,bersaldegenin-1-acetate, bersaldegenin-1,3,5-orthoacetate
Cytotoxic effect against adenocarcinomic human alveolar
basal epithelial A-549 cell line, promyelocytic leukemia
HL-60 cell line, oral adenosquamous carcinoma Cal-27 cell
line, and melanoma A2058 cell line
[127]
1 BD: B. daigremontianum; BH: B. × houghtonii; BP: B. pinnatum; and BT: B. tubiflorum. 2 nd: not determined.
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3. Plant Tissue Culture for Sustainable Valorization of Bioactive Compounds of Bryophyllum sp.
Currently, medicinal plants represent the source of more than 25% of drugs officially approved
by the Food and Drug Administration (FDA) and the European Medicinal Agency (EMA) for the
development of novel synthetic drugs [128]. Their derived by-products account for the 75–90% of
the total used in the primary healthcare systems of economically developed nations [129]. However,
only 6% of the plants have been studied from the pharmacological point of view and for 85% of them
their phytochemical potential has not been evaluated [130], which represents a vast territory of families
of plants with medicinal properties unexplored, such as Bryophyllum sp. Novel strategies, based on
plant biotechnology methodologies, are required to meet the growing global demand for products
derived from medicinal plants for industrial purposes in different sectors, such as the food, cosmetic,
and pharmaceutical industries [131].
Since then, plant biotechnology has constantly evolved, and it currently provides a reliable
methodology for the bioproduction of secondary metabolites with pharmacological value, by using
plant in vitro systems [132]. Consequently, plant tissue culture (PTC) became a basic biotechnological
methodology with countless applications in different areas of knowledge [133]. However, PTC must
face its own limitations, as it involves a set of highly specialized, usually expensive, techniques that are
extremely sensitive to multiple factors [134]. In this section, we will provide a deeper insight about the
key aspects of PTC, with particular focus on the methodology applied to Bryophyllum sp. (Figure 3).
Figure 3. Workflow diagram of Bryophyllum sp. valorization via plant tissue culture (PTC).
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3.1. PTC Establishment
The first step of a PTC protocol is the effective removal of pathogenic contaminants from the
selected plant material (Figure 3) [135]. Therefore, the sterilization of the explant surface is required
through a procedure that ensures convenient disinfection while maintaining its integrity, along with
aseptic handling in laminar flow cabinets [136].
In particular, our research group has developed a simple and reliable method for the disinfection
of epiphyllous buds of the adult plants of B. daigremontianum, B. × houghtonii and B. tubiflorum species
grown in greenhouse, which involves the use of common, safe and environmental-friendly disinfectant
agents [62,64,80,101,137]. The protocol includes an initial tap water wash of the buds overnight,
followed by a two-step stage, where the buds are rinsed in 70% ethanol (v/v) for 1 min, washed with
sterile distilled water and then rinsed in 0.4% (v/v) sodium hypochlorite with a few drops of Tween®-20
for 10 min. Finally, buds are gently washed with sterile distilled water and dried to remove persistent
residues of disinfection agents. After the establishment under aseptic conditions, disinfected buds are
placed and cultured in growth chambers under controlled conditions of photoperiod and temperature,
thus enabling an adequate culture development. This procedure represents an improvement on the
previously established disinfection protocols for Bryophyllum sp., in which slower procedures were
performed [138] with more concentrated disinfectants [139]; with greater losses of viability [140] and
explants integrity [141], or with more polluting agents, such as mercury chloride [142].
Plant Culture Media Composition
Plant culture media composition plays a crucial role in the success of PTC protocols, as the
nutrition of cultured plant materials depends directly on its ingredients [143]. As a general rule,
plant culture medium formulations contain a series of inorganic nutrients, divided into macro- and
micronutrients according to their requirements for plant physiology, along with organic nutrients,
such as vitamins [144]. Among the countless culture media formulations defined in PTC protocols,
the formulation described by Murashige and Skoog in 1962 [145], mostly known as MS medium,
is considered the universal medium to be applied as standard for different plant biotechnological
applications [146]. The universality of the MS medium is based on its high levels of nitrogen sources,
with a relatively high ratio of ammonium to nitrate [147]. However, it has recently been pointed out
that the composition of the MS medium is supra-optimal for some species and therefore harmful due
to an excessive concentration of ammonium ions [148,149].
Bryophyllum sp. are especially affected by excess of ammonium ion. This cation negatively
affects the growth of these species, due to a deterioration of CAM photosynthetic efficiency [150,151].
Although PTC of Bryophyllum sp. has been established using MS medium [138,139], better growth
and multiplication rates were achieved when the composition of the MS medium was modified, as it
has been shown by reducing the concentration of macronutrients by half for B. daigremontianum,
B. × houghtonii and B. tubiflorum [64,80,101].
3.2. Organogenesis and Plant Regeneration
Thus far, the information on the plant regeneration protocols for Bryophyllum sp. is limited.
Most publications focus on the establishment of indirect regeneration protocols [138–141,152]. Recently,
we have provided information on the effect of exogenous application of plant growth regulators (PGRs)
on the in vitro organogenesis of B. daigremontianum, B. × houghtonii and B. tubiflorum [137], pointing at
the concentration of the cytokinin 6-benzylaminopurine (BAP) as the most critical factor guiding this
process. Specifically, it was demonstrated that at operational concentrations of BAP (0.375–0.75 mg L−1)
both B. daigremontianum and B. × houghtonii present a higher frequency of direct shoot regeneration
than B. tubiflorum. In turn, B. tubiflorum was revealed as the most efficient species for the induction of
callus formation during indirect organogenesis [137]. These results highlight the complexity of the
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design of plant in vitro regeneration protocols and shed light into the organogenesis-related processes
of Bryophyllum sp., facing to the large-scale exploitation of these medicinal plants.
3.3. Micropropagation
After the establishment of axenic cultures, PTC protocols normally are followed by multiplication,
rooting and acclimatization stages, throughout the procedure called micropropagation (Figure 3),
with the objective of achieving a large number of fully-developed true-to-type individuals [135].
The singular asexual reproduction that takes place at leaf margins of Bryophyllum, results in
the clonal propagation of fully-developed epiphyllous buds, presenting individual aerial and
root systems [11,12]. For this reason, Bryophyllum constitutes an outstanding subgenus for the
micropropagation of different species. Nevertheless, the micropropagation of Bryophyllum is not
exempt from difficulties due to its particular metabolism and poor nutritional requirements [151].
In this sense, it was recently reported that ammonium, sulfur, molybdenum, copper, and sodium
play a crucial role on growth and plantlet formation on in vitro-cultured Bryophyllum in a
species-dependent manner [153]. Therefore, multiple nutritional modifications may be required
to achieve genotype-specific optimization, since mineral imbalances and interactions could directly
influence the success of PTC protocols, by affecting micropropagation performance [154], and causing
undesirable physiological disorders [148].
3.4. Establishment of Plant Suspension-Cultured Cells (PSCCs)
In the last decades, an increasing interest of plant biotechnology has been addressed to the
evaluation and valorization of medicinal plants, with the aim of exploring their phytochemical
potential and making it accessible to industrial applications [155]. In order to maximize the advantages
of PTC for the production of secondary metabolites, plant suspension-cultured cells (PSCCs) emerged
as a valuable biotechnological platform [156].
A single recent report is available for the establishment of PSCCs from B. × houghtonii [101].
In this work, the use of PSCCs from B. × houghtonii for the production of bioactive compounds was
reported, with a special focus on the operational aspects required for the establishment of plant cell
cultures, such as the determination of growth kinetics [101]. The typical four-phase growth behavior
was reported only after 8 days of culture, starting with an initial lag phase where cells acclimatize
to new culture conditions and no growth is observed. The lag phase is followed by the exponential
phase, where cell divisions occur massively, reported by a severe increase in cell biomass. Afterward,
a stationary phase is reached: cell growth stabilizes and the accumulation of secondary metabolites is
observed, before reaching death phase, in which cell death takes place due to a lack of nutrients [157].
PSCCs are considered a valuable biological platform for the application of several approaches
to enhance plant secondary metabolism, which have been widely exploited in the field of plant
biotechnology for the production of bioactive compounds: elicitation, precursor feeding, two-phase
culture system, and metabolic engineering [158]. Among them, elicitation is the most extended approach
applied to PSCCs, although it can be applied to many other culture types [159]. Due to the importance
of elicitation on the evaluation of medicinal plants and their phytochemical potential, the next section
will be focused on this phenomenon, with a particular focus on the elicitation of Bryophyllum sp.
3.5. Enhancement of Phenolic Compounds Production from Bryophyllum sp. via Elicitation
In the last years, great efforts regarding the improvement of plant secondary metabolism have
been made in the field of plant biotechnology, being the elicitation of PSCCs one of the most successful
approaches applied for the large-scale production of plant bioactive compounds [160]. A review of
the literature shows that the number of publications selected by Google Scholar® from the search
“elicitation of plant cell culture” is close to 15,000 entries in the last five years.
The term elicitation, as recently defined by Narayani and Srivastava (2017) [161], refers to “the
manipulation of biochemical and metabolic pathways, via stress induction, that can be implemented
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for enhancing secondary metabolite production and characterize the role of stress factors on plants
using plant cell and/or tissue cultures as model systems”. On this basis, different types of culture
may constitute precious biological platforms for the stimulation of plant secondary metabolism under
controlled conditions, by the administration of elicitors (Figure 3). In all cases, obtaining the maximum
viability and integrity of the elicited cultures is required in order to achieve an efficient and sustainable
production system [162].
Little information about the elicited production of bioactive compounds by Bryophyllum sp. can
be found in the literature. Recently, the elicitation of phenolic compounds from in vitro-cultured
Bryophyllum sp. subjected to nutritional stress has been reported by García-Pérez and co-workers
(2020) [62]. It was found that a decrease in the ammonium concentration in the culture medium causes
a 50% overproduction and accumulation of phenolic compounds in the aerial parts of B. × houghtonii.
The effect was less in magnitude in B. daigremontianum and B. tubiflorum [62]. In addition, the antioxidant
efficiency of the derived Bryophyllum extracts was assessed in terms of their free-radical scavenging
activity and lipid peroxidation inhibition [62,64], suggesting that in vitro-cultured B. × houghtonii can
be considered a medicinal species with an improved phytochemical potential [80], in comparison
to closely-related species, such as B. daigremontianum and B. tubiflorum. In this sense, due to its
phytochemical potential, PSCCs from B. × houghtonii were subjected to elicitation by cyclodextrins
(CDs) [101]. CDs are cyclic oligosaccharides able of forming inclusion complexes with hydrophobic
molecules. The results suggested that CDs elicited the production of phenolic compounds in
Bryophyllum PSCCs, as well as their associated free-radical scavenging activity. Specifically, it was
shown that CDs favored the accumulation of total phenols and flavonoids in the culture medium
(7.9 and 17.3-fold increases, respectively) after 7 days of culture, thus, preserving the integrity of the
cellular fraction for subsequent elicitation cycles [101].
Altogether, the application of novel approaches should be developed in order to reveal the full
phytochemical potential of Bryophyllum sp., based on the application of unexploited PTC strategies,
taking benefit of the countless advantages provided by PSCCs, committed to the enhancement of plant
secondary metabolite production.
4. Machine Learning for Optimizing the Biotechnological Valorization of Bryophyllum sp.
Along with this review, we provided evidence about the multifactorial behavior of PTC
methodologies and the production of secondary metabolites (Figure 3). Therefore, the elucidation
and characterization of such phenomena may require the development of complex experimental
designs, to reveal relevant interactions between factors, which are not feasible due to cost and time.
Furthermore, the analysis and interpretation of these complex experimental designs is difficult and,
in many cases, limited or incomplete [163].
Machine Learning (ML) techniques stand out as a cutting-edge alternative to detect the critical
factors behind a certain procedure, as well as a method to establish the influence of possible interactions
between them [164]. The application of ML algorithms allows the modeling of complex processes,
a powerful tool for making decisions and studying unknown phenomena [165]. Among the different ML
tools, the combination of artificial neural networks with fuzzy logic, commonly known as neuro-fuzzy
logic (NFL), constitutes a robust computational tool for the optimization and prediction of complex
processes [166]. Furthermore, NFL offers another advantage regarding the efficacy of predictive models,
thus providing direct knowledge from a detailed interpretation of the results, by the establishment of
simple “IF-THEN” rules, that facilitate making conclusions [167].
Concerning Bryophyllum sp., the application of NFL was already applied to the identification
of critical factors involved in plant in vitro nutrition [153] and organogenesis [137], as well as the
production of phenolic compounds [62].
In this sense, ML was able to identify the key mineral nutrients and their interactions, in order to
optimize the growth and reproduction of Bryophyllum sp. cultured in vitro. Among the 18 different
mineral nutrients used on MS formulation, ML detected that only five nutrients were critical on
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Bryophyllum in vitro culture, in a genotype-dependent manner [153]. Specifically, ammonium, sulfate,
sodium, molybdenum, and copper were selected by NFL as the critical factors guiding several
growth-related parameters, and the interaction between sulfate and molybdenum was widely reported
as responsible for most parameters: root length, plantlet formation, and aerial parts fresh weight [153].
ML was also employed for the modeling and predicting of Bryophyllum organogenesis
in vitro [137]. BAP concentration was assessed as the critical factor guiding this phenomenon on
B. daigremontianum, B. × houghtonii and B. tubiflorum; thus, predicting a minimal BAP concentration
required for the development of different organogenetic responses (0.35 mg L−1). On the contrary,
the application of auxins, such as indoleacetic acid (IAA), was outlined as an inhibitory factor
on the indirect shoot regeneration on B. tubiflorum, whereas no IAA influence was reported on
B. daigremontianum and B. × houghtonii [137].
Additionally, the production of phenolic compounds by in vitro-cultured Bryophyllum sp. was
optimized using ML [62]. It was observed that phenolic compounds accumulation achieved the
maximum concentrations in the aerial parts of cultured plants under low ammonium concentrations
(<15 mM). Moreover, the extraction of total phenolic compounds was enhanced by the use of
55–85% aqueous methanol, whereas flavonoids were mostly extracted with higher methanol
concentrations in water (>85%). In addition, the antioxidant potential of Bryophyllum extracts,
in terms of radical-scavenging activity, was shown to be improved using 55–85% MeOH as solvent on
B. × houghtonii cultured under low ammonium concentrations [62]. Furthermore, these experimental
conditions for maximizing the antioxidant activity of B. × houghtonii were also validated in terms of
preventing lipid oxidation [64] and plant in vitro growth [153]; thus, assessing the effectiveness of ML
on the valorization of Bryophyllum.
5. Concluding Remarks and Future Perspectives
This review focuses on the ethnomedicinal uses of Bryophyllum sp., and their main phytoconstituents,
responsible for its biological and pharmacological properties (cytotoxic, sedative, insecticidal, antiviral,
and anticancer activities).
It has also been described how the development of optimal methods of plant tissue culture for
Bryophyllum sp. can lead to the valorization of the bioactive compounds of these species, which are
highly promising in therapeutics as antioxidant and anti-tumor agents. In this sense, the application
of machine learning technology to model and optimize the production of phytochemicals is of
extraordinary interest as it could favor their large-scale biotechnological exploitation in the cosmetic,
food, and pharmaceutical industries.
In our opinion, the current trends and future challenges on the research of non-well characterized
medicinal plants are: (i) the combination of plant in vitro systems, using molecular approaches,
and nutritional studies [128], with the purpose of characterizing their full biosynthetic potential;
(ii) the enhancement of secondary metabolism throughout the application of metabolic engineering,
as it has been performed in the cases of trans-resveratrol [168] and terpenoid indole alkaloids [169];
(iii) the application of high throughput technologies, such as metabolomics, for the characterization of
metabolic fingerprinting associated to elicitation of PSCCs, in response to plant stress, at a biochemical
and biosynthetic level [170,171]. Finally, the combination of PTC and ML with omics technologies will
assist to the establishment of new perspectives on the field of phytochemistry and the study of the
biosynthetic potential of unexplored plants, as it is the case of Bryophyllum. Nowadays, the cornerstone
in clinical management includes two easy concepts that are dietary modification associated with
improvement of physical activity, also defined as lifestyle change [172,173] through a revaluation to
popular medicine.
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